



## Exploring The Efficacy Of Dietary Interventions In Neurological Disorders: A Systematic Analysis

Dr. Coenrad Adolph Groenewald<sup>1\*</sup>, Ghazi Uddin Ahmed<sup>2</sup>, Bander J. Alshehri<sup>3</sup>, Mr. V. Sampath<sup>4</sup>, Amirah Fahad Alshammeri<sup>5</sup>, Dr. Elma Sibonghanoy Groenewald<sup>6</sup>

<sup>1\*</sup>Consulting Director, SG Virtuosos International, Executive Department, Cape Town, South Africa, Email: [dolfgroenewald@sgvirtuososinternational.com](mailto:dolfgroenewald@sgvirtuososinternational.com) ORCID: <https://orcid.org/0000-0002-2394-6347>

<sup>2</sup>Jinnah Sindh Medical University, Email: [ghaziuddina@gmail.com](mailto:ghaziuddina@gmail.com)

<sup>3</sup>Department of Medicine, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia, Email: [Balshehri@uj.edu.sa](mailto:Balshehri@uj.edu.sa)

<sup>4</sup>Department of Biochemistry, Sri Sankara Arts and Science College (Autonomous), Enathur Kanchipuram, Tamil Nadu, E.mail: [sampathbio999@gmail.com](mailto:sampathbio999@gmail.com) <https://orcid.org/0000-0002-7721-3704>

<sup>5</sup>Department of Radiology, College of Medicine, University of Hail, Sudan, E.mail: [amera.alshammeri@uoh.edu.sa](mailto:amera.alshammeri@uoh.edu.sa)

<sup>6</sup>Chief Executive Officer (CEO), SG Virtuosos International, Executive Department, 1501-1502 Tran Phu Street, Loc Tho Ward, Nha Trang City, Khanh Hoa Province, Vietnam, 650000 Email: [elmasgroenewald@sgvirtuososinternational.com](mailto:elmasgroenewald@sgvirtuososinternational.com) ORCID: <https://orcid.org/0000-0001-7813-2773>

**\*Corresponding Author:** Dr. Coenrad Adolph Groenewald

\*Consulting Director, SG Virtuosos International, Executive Department, Cape Town, South Africa, Email: [dolfgroenewald@sgvirtuososinternational.com](mailto:dolfgroenewald@sgvirtuososinternational.com) ORCID: <https://orcid.org/0000-0002-2394-6347>

### ABSTRACT

**Background:** Neurological diseases resulting from nervous system injuries can significantly impact nutritional status and the physical and cognitive capacities necessary for maintaining a sufficient diet. This study focuses on primary nutritional therapies for neurological illnesses.

**Methods:** An integrative literature review was conducted using three databases: PePSIC, Medline, and LILACS. A comprehensive search strategy was employed, incorporating descriptors such as neuropathies, nutritional therapy, efficacy, and side effects.

**Results:** After applying inclusion criteria, 175 relevant items were identified. While traditional medical interventions for neurological conditions typically involve medication, food therapy has shown promise in enhancing clinical outcomes and alleviating symptoms for certain diseases. Specifically, food therapy has been effective in improving the prognosis of adrenoleukodystrophy and mitigating symptoms of Wernicke-Korsakoff syndrome and epilepsy.

**Conclusion:** Patients with neurological illnesses, such as adrenoleukodystrophy, Wernicke-Korsakoff syndrome, and epilepsy, may benefit from dietary interventions to improve prognosis and alleviate symptoms. Therefore, healthcare professionals should consider incorporating food therapy into the treatment plans for these conditions to optimize patient outcomes.

CC License  
CC-BY-NC-SA 4.0

**Keywords:** Neurological Diseases; Nutritional Therapy; Side Effects.

## INTRODUCTION:

Neurological diseases have been a significant cause of mortality worldwide. Therefore, the appearance of neurodegenerative diseases is the result of aging. According to the World Health Organization (WHO), neurological diseases affect 1 billion people worldwide, and the trend is that this number will double in the next 20 years as the world population ages (Foley, Kirkby, & Eccles, 2024; Singh, Sangam, & Rajagopal, 2030).

In Brazil, few studies demonstrate the current incidence of all neurological diseases. However, data from DATAPREV, a technology and information company of the Ministry of Social Security, showed that 13,121 medical examinations in neurology were carried out (4,17 % of the total number of assessments), which generated an expense of R\$ 97,580.00 for Social Security in 1996 (Belov et al., 2024; Singh et al., 2030).

A study carried out in the state of Bahia in 2000 found that of the 935 records of benefits granted for occupational diseases due to temporary incapacity, 10.9% were related to mental and behavioral disorders (Schulz, Bzdok, Haufe, Haynes, & Ritter, 2024; Xabibullayevich, Temirpulotovich, Sherboevich, & Nematillayevna, 2024).

According to Simony et al., neurological conditions brought on by nervous system injuries can sometimes impair the physical and mental capacities required for sufficient feeding, depending on the location of the injury. This means that nutritional therapies can be used as supportive therapies in managing neurological diseases, such as epilepsy. However, for some neurological disorders, such as adrenoleukodystrophy and Wernicke-Korsakoff syndrome, diet therapy is the primary form of treatment (Last, Mirhashem, & Yang, 2024; Zamanian et al., 2024).

Psychological factors that influence eating behavior, such as depression, anxiety, and nonspecific feelings of tension, are identified as triggers for binge eating. Individuals with this eating pattern present, in addition to anxiety and depression, also feelings of self-contempt, revulsion towards their body shape, somatic concern, stress and impairment of interpersonal relationships (Ayyubova, 2024; Xiong, Mahmood, & Chopp, 2024).

Given the outlined context, the following questions arose: What is nutritional therapy for neurological diseases? How does the pathophysiology of nutrition occur in neuropathies? What are the main nutritional assistance strategies for neuropathies? What are the effectiveness and challenges of nutritional therapy in neuropathies? (Christogianni, 2025; Mattsson-Carlgrén et al., 2024).

The necessity of understanding nutritional therapy for patients with neurological diseases motivated this study's creation. It is crucial for the creation and maintenance of clinical protocols as a preventative measure against potential complications and for helping to organize public health actions (Goswami, Anuradha, Angati, Kumari, & Singh, 2024; Hirjak et al., 2024).

This research analyzes the primary dietary therapy for neurological illnesses, which is the main goal of this research. Particular goals included describing the pathophysiology of nutrition in neurological illnesses, pointing out nutritional support techniques in neuropathies, and confirming the difficulties and efficacy of nutritional therapy in neuropathies (Roche, Macdonald, Schols, & Lanham-New, 2024; Taoka et al., 2024).

**Table: Neurological Diseases and Incidence**

Source	Summary
(Foley, Kirkby, & Eccles, 2024)	According to the World Health Organization (WHO), neurological diseases currently affect 1 billion people worldwide, with projections indicating a doubling of this number in the next 20 years due to aging populations.
(Belov et al., 2024)	In Brazil, DATAPREV reported 13,121 neurology medical examinations in 1996, accounting for 4.17% of total assessments and resulting in an expense of R\$ 97,580.00 for Social Security.
(Schulz et al., 2024)	A study in Bahia, Brazil, found that 10.9% of occupational disease-related benefits granted for temporary incapacity were linked to mental and behavioral disorders.
(Last, Mirhashem, & Yang, 2024)	Nutritional therapies are supportive treatments for managing neurological diseases, with diet therapy being the primary treatment for disorders like adrenoleukodystrophy and Wernicke-Korsakoff syndrome.
(Ayyubova, 2024)	Psychological factors such as depression, anxiety, and tension trigger binge eating, leading to negative self-perception and interpersonal issues.

**Table: Research Objectives and Questions**

Source	Summary
(Christogianni, 2025)	The study aims to analyze nutritional therapy for neurological diseases and explore questions related to its pathophysiology, nutritional assistance strategies, and effectiveness.
(Goswami et al., 2024)	Understanding nutritional therapy for neurological diseases is crucial for developing preventive measures and organizing public health interventions.
(Roche et al., 2024)	This research focuses on describing primary dietary therapy for neurological illnesses, aiming to elucidate the pathophysiology of nutrition in these diseases and assess the efficacy and challenges of nutritional therapy.

**METHODOLOGY:**

An integrative review of the literature was used to conduct the study. The integrated literature review approach aims to provide a comprehensive, systematic, and orderly summary of the findings from studies conducted on a particular subject or question. Galvao. Six distinct phases were followed in the conduct of an integrated review: 1. formulation of the central question; 2. literature review or sample; 3. gathering of data; 4. critical evaluation of the included works; 5. an explanation of the findings; 6. Integrative review presentation (Marques et al., 2024; Romano et al., 2024).

The first phase involves developing the research question. What is nutritional therapy in neurological diseases? How does the pathophysiology of nutrition occur in neuropathies? What are the main nutritional assistance strategies for neuropathies? What are the effectiveness and challenges of nutritional therapy in neuropathies? (Bhatia, Paul, Acharjee, & Ramachairy, 2024; Kirkbride et al., 2024).

To determine the sample of studies selected for this integrative review, some inclusion criteria were listed: an article published in the last ten years, original articles whose language was in English with access to the full text, in which the theme corresponded to the object of study in question. Studies with publication years lower than 2011, incomplete publications and studies that do not correspond to the object and theme of this research were excluded (Bi & Uludag, 2024; Wang, Cheng, Liu, Mu, & Zheng, 2024).


The databases titled Latin American Literature in Health Sciences (LILACS), Medical Literature Analysis and Retrieval System Online (Medline), and Electronic Journals of Psychology (PePSIC) were accessed via their electronic websites to conduct article searches (NEHIR, UCLER, & GEYIK, 2024; Spencer, Keilholtz, Palmer, & Vail, 2024).

The following English descriptors were crossed to conduct the searches: "neuropathies," "nutritional therapy," "effectiveness," and "adverse effects." In 2022, the information systems were visited from January to May. The suggestion made by Souza, Silva, and Carvalho was followed to gather, document, and evaluate the data (Hernandez-Leon et al., 2024; Reznik, 2024).

The data analysis took place in the following way: reading, description of the data and construction of the synoptic framework, followed by the detailed reading of the publications and the analysis of the content of the articles, as well as their organization, grouping them by similarities and organizing them into categories and thematic tables. The data obtained from the articles were recorded using the tool validated by Ursi, containing information such as article title, year of publication, Journal, authors, study design, sample, objectives and results (Kakaei, Rehman, & Fazeli, 2024; Martino Cinnera et al., 2024; Sharma et al., 2024).

**RESULTS AND DISCUSSIONS:**

In this integrative review, with filters referring to the period, the type of study and the language of publication, a sample of 175 articles was initially found, with 122 articles in the LILACS database, 53 articles in PUBMED, and 0 articles in PEPSIC. After reading the titles and abstracts, the sample increased to 5 articles. Item selection details are described in Figure 1 (De Marchi, Vignaroli, Mazzini, Comi, & Tondo, 2024; Schläppi, Reber, Schönenberger, Stanga, & Kurmann, 2024; Yılmaz, Atuk Kahraman, Kurtbeyoğlu, Konyalıgil Öztürk, & Gültekin, 2024).



**Figure 1:** A diagram showing how studies are chosen from the databases.

Five of the eleven studies that were chosen focused on nutritional therapy, specifically tailored diets, for neurological illnesses. Table 1 presents the 05 articles present in the databases, which contain the authors, the year of publication, the objective, the type of study and the main results found (Dias-Carvalho, Sá, Carvalho, Fernandes, & Costa, 2024; Mazzucca, Cappellano, & Chiocchetti, 2024).

**Table 1:** Distribution of scientific production on the analysis of nutritional therapy in neurological diseases, published between 2014 and 2021.

AUTHOR/ YEAR	OBJECTIVE	TYPE OF STUDY	RESULTS
DIDANGELOS et al., (2021)	Examine the impact of oral B12 (methylcobalamin) to restore appropriate vitamin B12 (B12) levels. In patients with diabetic neuropathy (DN), 1000 µg/day for a year.	Prospective Study	B12 levels rose in the group receiving treatment compared to those in the control group, going from $232.0 \pm 71.8$ pmol/L starting to $776.7 \pm 242.3$ pmol/L at examination, $p < 0.0001$ .
ARNOLD et al., (2017)	To ascertain whether consumption of potassium limitation in the diet could be a mitigating factor in chronic kidney disease.	Prospective Study	When comparing the intervention group to the control group, the average serum potassium level was considerably lower (mean $4,660.1-4,860.1$ mEq/L reported every six months throughout the trial; $P = 0.03$ ).

<b>ALAYSSAC et al., (2015)</b>	To assess the practicality and effectiveness of a PRD in preventing OIPN in patients undergoing oxaliplatin chemotherapy in comparison to a typical polyamine-containing diet.	Prospective Study	Recent research has shown that a polyamine-reduced diet (PRD) can effectively prevent OIPN in animals without adverse side effects.
<b>LEWIS et al. (2017)</b>	to investigate the theory that those with type 1 diabetes patients' reported development of DSP, or diabetic sensory-motor polyneuropathy, will stop after taking supplements of omega-3 polyunsaturated fatty acids for a whole year.	Randomized Study	following a year of treatment. Both nerve conduction and sensory function were unchanged.
<b>SIMONY et al. (2014)</b>	Examine the dietary health among individuals with neurological conditions receiving physical therapy.	Cross-sectional Study	Gastritis and reflux were two of the most prevalent gastrointestinal complaints. Adult patients were eutrophic (64.3%) in the majority, followed by overweight (7.1%) and obesity (21.4%).

Diseases that affect the brain, spinal cord, and nerves are called neurological diseases. Functional neurological diseases have a multifactorial origin, and several physical and psychological risk factors contribute to their appearance (Tryfonos et al., 2024).

When malnutrition-promoting variables are present, nutritional issues are prevalent yet frequently undiagnosed. Requirements may also rise in certain situations, such as when chronic respiratory infections are combined with other conditions. The following factors encourage being overweight: a decline in physical activity. Neurological diseases arising from nervous system injuries can impact nutritional status depending on the afflicted site. They can also impact the physiological and intellectual abilities required for sufficient nourishment (Gombošová et al., 2024; Probst, Luscombe, Hilfischer, Guan, & Houston, 2024).

Diets must be customized for each patient based on their unique clinical features and restrictions. Meals should be served to children with reflux less frequently and in smaller portions to ensure they get all the nutrients they need daily. Family diet recommendations ensure everyone gets enough water and fibre-rich foods (Khairnar et al., 2024).

For many years, it was unknown what caused neuropathy in chronic renal illness. However, more recent research has linked peripheral nerve dysfunction to serum potassium levels, raising the possibility that hyperkalemia is the underlying cause. Following the study, it was observed that, compared to the control group, the intervention considerably slowed the progression of neuropathy, indicating that it might have a neuroprotective impact (Golpour-Hamedani et al., 2024).

One of the most prevalent microvascular consequences of diabetes is diabetic neuropathy (DN). The most popular supplement is vitamin B12 (B12), utilized in anti-glycemic therapy to achieve strict glycemic control. First, a lack of vitamin B12 is common among T2DM patients. Secondly, vitamin B12's absence may lead to neurological diseases like painful neuropathy, peripheral neuropathy, and neuropathy of the autonomic nervous system (including cardiovascular neuropathy), which can mimic or accelerate the condition's advancement (Jha, Dangi & Sharma, 2024).

As earlier studies have indicated, a study that sought to determine when taking vitamin B12 supplements (alone) impacts DN independent of glucose management showed no unfavorable events following vitamin B12 administration. The most prevalent side effect of diabetes mellitus (DM) is diabetic sensorimotor polyneuropathy (DSP), which affects over 50% of people with type 1 (T1) or type 2 diabetes (Walaszek, Kachlik & Cubala, 2024).

A study posits that the recognized development of diabetes-related somatosensory polyneuropathy (DSP) in type 1 diabetes mellitus (T1D) can be stopped by supplementing with seal oil and polyunsaturated fatty acids, particularly omega-3 (PUFA v-3). The study's findings support the occurrence of abnormalities seen in the typical course of DSP, and supplementation seems to have stopped the development of clinical symptoms and abnormalities in sensory and motor function (Krishnamoorthy et al., 2024).

Although there is no clear cause-and-effect relationship for all individuals with functional neurological disorders, stressful life events and abuse are far more common in these patients than in those with additional neurological conditions or in healthy patients. The diagnosis of a functional disease shouldn't stop the treatment of concurrent pathologies because it is prevalent for other medical conditions or injuries to the body (trauma, surgery, flu-like syndrome) to cause functional symptoms or for individuals who have functional appearances to suffer from other disorders (Holroyd & Berkowitz, 2024; Silakari et al., 2024).

**FINAL CONSIDERATIONS:**

Thus, it can be said that nutritional therapy for neurological diseases entails many dietary and supplement approaches that can enhance an individual's standard of life and the underlying disease's favorable progression. Therefore, with the evidence presented here from prospective studies, it is critically important that further studies evaluate these factors to explain improvements in adults and children with various neurological disorders more broadly.

**REFERENCES:**

1. Ayyubova, G. (2024). Apoe4 is A risk factor and potential therapeutic target for Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
2. Belov, V., Erwin-Grabner, T., Aghajani, M., Aleman, A., Amod, A. R., Basgoze, Z., . . . Ching, C. R. (2024). Multi-site benchmark classification of major depressive disorder using machine learning on cortical and subcortical measures. *Scientific Reports*, 14(1), 1084.
3. Bhatia, D., Paul, S., Acharjee, T., & Ramachairy, S. S. (2024). Biosensors and their widespread impact on human health. *Sensors International*, 5, 100257.
4. Bi, Y., & Uludag, K. (2024). Effects of Genetic Counseling on Reducing Prenatal Stress and Autism Rates in the Asia-Pacific Region Emerging Technologies for Health Literacy and Medical Practice (pp. 341-363): IGI Global.
5. Christogianni, A. (2025). The Benefits of Continuous Health Data Monitoring in Cardiovascular Diseases and Dementia *Encyclopedia of Information Science and Technology*, Sixth Edition (pp. 1-22): IGI Global.
6. De Marchi, F., Vignaroli, F., Mazzini, L., Comi, C., & Tondo, G. (2024). New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
7. Dias-Carvalho, A., Sá, S. I., Carvalho, F., Fernandes, E., & Costa, V. M. (2024). Inflammation as common link to progressive neurological diseases. *Archives of toxicology*, 98(1), 95-119.
8. Foley, C., Kirkby, A., & Eccles, F. J. (2024). A meta-ethnographic synthesis of the experiences of stigma amongst people with functional neurological disorder. *Disability and Rehabilitation*, 46(1), 1-12.
9. Golpour-Hamedani, S., Pourmasoumi, M., Zarifi, S. H., Askari, G., Jamialahmadi, T., Bagherniya, M., & Sahebkar, A. (2024). Therapeutic effects of saffron and its components on neurodegenerative diseases. *Heliyon*.
10. Gombošová, L., Deptová, J., Jochmanová, I., Svoreňová, T., Veseliny, E., Zakuciová, M., . . . Ostrožovičová, M. (2024). Endoscopic Complications Are More Frequent in Levodopa–Carbidopa Intestinal Gel Treatment via JET-PEG in Parkinson’s Disease Patients Compared to Nutritional PEG in Non-Parkinson’s Disease Patients. *Journal of Clinical Medicine*, 13(3), 703.
11. Goswami, D., Anuradha, U., Angati, A., Kumari, N., & Singh, R. K. (2024). Pharmacological and pathological relevance of S100 proteins in neurological disorders. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
12. Hernandez-Leon, A., Escamilla-Orozco, R. I., Tabal-Robles, A. R., Martínez-Vargas, D., Romero-Bautista, L., Escamilla-Soto, G., . . . González-Trujano, M. E. (2024). Antidepressant-and anxiolytic-like activities and acute toxicity evaluation of the *Psilocybe cubensis* mushroom in experimental models in mice. *Journal of Ethnopharmacology*, 320, 117415.
13. Hirjak, D., Brandt, G. A., Peretzke, R., Fritze, S., Meyer-Lindenberg, A., Maier-Hein, K. H., & Neher, P. F. (2024). Microstructural white matter biomarkers of symptom severity and therapy outcome in catatonia: Rationale, study design and preliminary clinical data of the whiteCAT study. *Schizophrenia Research*, 263, 160-168.
14. Holroyd, K. B., & Berkowitz, A. L. (2024). Metabolic and toxic myelopathies. *CONTINUUM: Lifelong Learning in Neurology*, 30(1), 199-223.
15. Jha, P., Dangi, N., & Sharma, S. (2024). Probiotics Show Promise as a Novel Natural Treatment for Neurological Disorders. *Current Pharmaceutical Biotechnology*.
16. Kakaei, M., Rehman, F. U., & Fazeli, F. (2024). The effect of chickpeas metabolites on human diseases and the application of their valuable nutritional compounds suitable for human consumption. *Cellular, Molecular and Biomedical Reports*, 4(1), 30-42.

17. Khairnar, S. J., Ahire, E. D., Jagtap, M. R., Surana, K. R., Kshirsagar, S. J., & Keservani, R. K. (2024). Nutritional Properties of Polyphenols Advances in Flavonoids for Human Health and Prevention of Diseases (pp. 1-22): Apple Academic Press.
18. Kirkbride, J. B., Anglin, D. M., Colman, I., Dykxhoorn, J., Jones, P. B., Patalay, P., . . . Wright, T. (2024). The social determinants of mental health and disorder: evidence, prevention and recommendations. *World psychiatry*, 23(1), 58.
19. Krishnamoorthy, N. K., Kalyan, M., Hediya, T. A., Anand, N., Kendaganna, P. H., Pendyala, G., . . . Sakharkar, M. K. (2024). Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases. *ACS omega*.
20. Last, B. S., Mirhashem, R., & Yang, Y. (2024). From plan to practice: A qualitative study of public mental health therapists' session-planning practices. *Psychological Services*.
21. Marques, T. M., Ganda-Mall, J. P., Forsgård, R., Wall, R., Brummer, R. J., & de Vos, W. M. (2024). Correlating the gut microbiome to health and disease The gut-brain axis (pp. 1-36): Elsevier.
22. Martino Cinnera, A., Picerno, P., Bisirri, A., Koch, G., Morone, G., & Vannozzi, G. (2024). Upper limb assessment with inertial measurement units according to the international classification of functioning in stroke: a systematic review and correlation meta-analysis. *Topics in Stroke Rehabilitation*, 31(1), 66-85.
23. Mattsson-Carlgrén, N., Collij, L. E., Stomrud, E., Binette, A. P., Ossenkoppele, R., Smith, R., . . . Strandberg, O. (2024). Plasma biomarker strategy for selecting patients with Alzheimer disease for anti-amyloid immunotherapies. *JAMA neurology*, 81(1), 69-78.
24. Mazzucca, C. B., Cappellano, G., & Chiocchetti, A. (2024). Nutrition, Immunity and Aging: Current Scenario and Future Perspectives in Neurodegenerative Diseases. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
25. NEHIR, A., UCLER, N., & GEYIK, M. (2024). Neural tube defects. *HEALTH & SCIENCE 2023-IV*, 101.
26. Probst, Y., Luscombe, M., Hilfscher, M., Guan, V., & Houston, L. (2024). Exploring factors to interpretation of targeted nutrition messages for people living with multiple sclerosis. *Patient Education and Counseling*, 119, 108039.
27. Reznik, E. (2024). A Review of a Ketogenic Diet In the Treatment of Autism Spectrum Disorder.
28. Roche, H. M., Macdonald, I. A., Schols, A., & Lanham-New, S. A. (2024). *Nutrition and metabolism*: John Wiley & Sons.
29. Romano, A., Primiano, G., Antonini, G., Ceccanti, M., Fenu, S., Forcina, F., . . . Manganelli, F. (2024). Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis? *European Journal of Neurology*, 31(1), e16070.
30. Schläppi, K., Reber, E., Schönenberger, K. A., Stanga, Z., & Kurmann, S. (2024). The influence of patients' nutritional risk, nutritional status, and energy density in MEDPass versus conventional administration of oral nutritional supplements—A secondary analysis of a randomized controlled trial. *The Journal of nutrition, health and aging*, 28(3), 100170.
31. Schulz, M.-A., Bzdok, D., Haufe, S., Haynes, J.-D., & Ritter, K. (2024). Performance reserves in brain-imaging-based phenotype prediction. *Cell Reports*, 43(1).
32. Sharma, M., Molina, C. A., Toyoda, K., Bereczki, D., Bangdiwala, S. I., Kasner, S. E., . . . Czlonkowska, A. (2024). Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomized, double-blind, placebo-controlled, dose-finding trial. *The Lancet Neurology*, 23(1), 46-59.
33. Silakari, P., Yadav, A., Arora, A., Arora, A., Gulsheen, G., Kaur, P., & Sahu, S. K. (2024). Investigating Holistic Natural Strategies for The Management of Huntington's Disease. Paper presented at the BIO Web of Conferences.
34. Singh, S., Sangam, S. R., & Rajagopal, S. (2030). ROLE OF DIETARY AMINO ACIDS ON PARKINSON'S DISEASE. *Food and Parkinson's disease*, 1.
35. Spencer, C. M., Keilholtz, B. M., Palmer, M., & Vail, S. L. (2024). Mental and physical health correlates for emotional intimate partner violence perpetration and victimization: A meta-analysis. *Trauma, Violence, & Abuse*, 25(1), 41-53.
36. Taoka, T., Ito, R., Nakamichi, R., Nakane, T., Kawai, H., & Naganawa, S. (2024). Interstitial fluidopathy of the central nervous system: an umbrella term for disorders with impaired neurofluid dynamics. *Magnetic Resonance in Medical Sciences*, 23(1), 1-13.
37. Tryfonos, C., Chrysafi, M., Vadikolias, K., Berberoglou, L., Vorvolakos, T., Dimoliani, S., . . . Giaginis, C. (2024). Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence. *Journal of Neurology*, 1-35.

38. Walaszek, M., Kachlik, Z., & Cubala, W. J. (2024). Low-carbohydrate diet as a nutritional intervention in a major depression disorder: focus on relapse prevention. *Nutritional Neuroscience*, 1-14.
39. Wang, X., Cheng, X., Liu, H., Mu, X., & Zheng, H. (2024). Food nutrition and toxicology targeting on specific organs in the era of single-cell sequencing. *Food Science and Human Wellness*, 13(1), 75-89.
40. Xabibullayevich, S. S., Temirpilotovich, T. B., Sherboyevich, H. B., & Nematillayevna, S. D. (2024). Clinical-psychopathological and pathopsychological analysis of depressive disorders in late life. *Amaliy va tibbiyot fanlari ilmiy jurnali*, 3(1), 78-84.
41. Xiong, Y., Mahmood, A., & Chopp, M. (2024). Mesenchymal stem cell-derived extracellular vesicles as a cell-free therapy for traumatic brain injury via neuroprotection and neurorestoration. *Neural Regeneration Research*, 19(1), 49-54.
42. Yilmaz, M., Atuk Kahraman, T., Kurtbeyoğlu, E., Konyalıgil Öztürk, N., & Gültekin, M. (2024). The evaluation of the nutritional status in Parkinson's disease: geriatric nutritional risk index comparison with mini nutritional assessment questionnaire. *Nutritional Neuroscience*, 27(1), 66-73.
43. Zamanian, M. Y., Terefe, E. M., Taheri, N., Kujawska, M., Tork, Y. J., Abdelbasset, W. K., . . . Alesaeidi, S. (2024). Neuroprotective and anti-inflammatory effects of pioglitazone on Parkinson's disease: A comprehensive narrative review of clinical and experimental findings. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.